Skip to main content
4DMEDICAL LIMITED logo

4DMEDICAL LIMITED — Investor Relations & Filings

Ticker · 4DX ISIN · AU0000095416 LEI · 9845000A8F12A6A6FD75 ASX Telecommunications, computer programming, consultancy, computing infrastructure, and other information service activities
Open in API
Filings indexed 546 across all filing types
Latest filing 2023-02-27 Interim / Quarterly Rep…
Country AU Australia
Listing ASX 4DX

About 4DMEDICAL LIMITED

https://4dmedical.com/

4DMedical Limited develops non-invasive respiratory imaging solutions centered on its proprietary XV Technology. This platform utilizes advanced algorithms to transform standard X-ray sequences into four-dimensional quantitative data, visualizing regional lung function in motion. The flagship XV Lung Ventilation Analysis Software (XV LVAS) provides clinicians with detailed maps of airflow distribution throughout the respiratory cycle, facilitating the early detection and monitoring of chronic conditions such as COPD, asthma, and interstitial lung disease. By providing objective, high-resolution insights into lung ventilation without the limitations of traditional pulmonary function tests, the company's cloud-based diagnostic tools aim to improve clinical workflows and patient management. The integration of artificial intelligence further enhances its capability to deliver precise, automated lung tissue analysis.

Recent filings

Filing Released Lang Actions
Appendix 4D and Half-Year Financial Report 24 pages 630.6KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Half-Year Financial Report 2023' and covers the period from 1 July 2022 to 31 December 2022, indicating it is a financial report for a half-year period. It contains detailed financial data including revenue, net loss, operating expenditure, and cash balances. It also includes a Directors' report, Auditor's independence declaration, consolidated financial statements, and notes to the financial statements. The length of the document is substantial (15,000 characters), and it contains actual financial statements and substantive financial analysis, not just an announcement or summary. The presence of half-year financial data and comprehensive financial statements aligns with the definition of an Interim / Quarterly Report (IR). Therefore, the appropriate classification is IR with high confidence. H1 2023
2023-02-27 English
4DMedical Reports 1H FY2023 Results 6 pages 476.3KB
Interim / Quarterly Report Classification · 95% confidence The document is an ASX announcement dated 28 February 2023 reporting the financial and operational progress of 4DMedical Limited for the first half of fiscal year 2023 (1H FY2023). It includes detailed financial performance data such as total income, revenue, net loss, cash balance, and operating expenditure for the half-year period. It also discusses clinical trial results, commercial developments, leadership changes, and strategic updates. The presence of comprehensive financial data and analysis for a half-year period indicates this is a half-year financial report. The document is about a period shorter than a full fiscal year and contains substantive financial data and analysis, which fits the definition of an Interim / Quarterly Report (IR). It is not a brief announcement or a simple notice, nor is it a full annual report or earnings release. Therefore, the correct classification is IR with high confidence. H1 2023
2023-02-27 English
Quarterly Activity Report and Appendix 4C for Q2 FY2023 11 pages 2.4MB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Quarterly Activity Report and Appendix 4C for Q2 FY2023' and dated 31 January 2023. It contains detailed financial and operational information for the quarter ended 31 December 2022, including cash flow data, revenue figures, government grants, and operational highlights. The presence of Appendix 4C (a cash flow report) and substantive financial data for a quarter indicates this is a comprehensive interim/quarterly financial report. The document is about 15,000 characters long, which is consistent with a full report rather than a brief announcement. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q2 2023
2023-01-30 English
Notification of cessation of securities - 4DX 5 pages 26.1KB
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Notification of cessation of +securities' and details the cessation of certain options and securities for 4DMEDICAL LIMITED. It includes specific information about the securities that have ceased, reasons for cessation, dates, and the updated issued capital following these changes. There is no financial performance data, earnings information, or management discussion. The document is an official announcement regarding changes in the company's issued securities, specifically the cessation of certain options. This fits the category of Share Issue/Capital Change announcements, as it relates to changes in the company's capital structure due to cessation of securities.
2023-01-10 English
Notification regarding unquoted securities - 4DX 10 pages 39.9KB
Share Issue/Capital Change Classification · 95% confidence The document is a detailed notification about the issue of unquoted equity securities, specifically options issued under an employee incentive scheme. It includes information about the number of securities issued, their terms, exercise prices, expiry dates, and mentions key management personnel receiving options. The document references compliance with ASX listing rules and provides links to related documents. This type of filing is a formal announcement of new securities issued by the company, which fits the category of Share Issue/Capital Change (SHA). It is not an annual report, earnings release, or management discussion, nor is it a regulatory certification or voting result. The length and detail confirm it is the actual notification, not just an announcement of a report publication. Therefore, the correct classification is SHA with high confidence.
2022-12-22 English
Appendix 3Y - AF 3 pages 256.0KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by a company director, including direct and indirect interests, number of securities held before and after the change, and nature of the change (grant of options). This is a formal notification of personal share transactions by a company director. The document does not contain financial statements or company performance data but focuses solely on director share dealings. Therefore, it fits the definition of 'Director's Dealing' filings.
2022-12-22 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.